Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Nov 1;59(11):1935.
doi: 10.3390/medicina59111935.

Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study

Affiliations
Observational Study

Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study

Ludovico Abenavoli et al. Medicina (Kaunas). .

Abstract

Background and Objectives: Inflammatory bowel disease (IBD) is a condition characterized by chronic intestinal inflammation. We can identify two major forms: Crohn's disease (CD) and ulcerative colitis (UC). One of the extraintestinal manifestations of IBD is nonalcoholic fatty liver disease (NAFLD). IBD and NAFLD share common pathogenetic mechanisms. Ultrasound (US) examination is the most commonly used imaging method for the diagnosis of NAFLD. This cross-sectional observational retrospective study aimed to evaluate the US prevalence of NAFLD in IBD patients and their clinical features. Materials and Methods: A total of 143 patients with IBD underwent hepatic US and were divided into two different groups according to the presence or absence of NAFLD. Subsequently, new exclusion criteria for dysmetabolic comorbidities (defined as plus) were applied. Results: The US prevalence of NAFLD was 23% (21% in CD and 24% in UC, respectively). Most IBD-NAFLD patients were male and older and showed significantly higher values for body mass index, waist circumference, disease duration, and age at onset than those without NAFLD. IBD-NAFLD patients showed a significantly higher percentage of stenosing phenotype and left-side colitis. Regarding metabolic features, IBD-NAFLD patients showed a significantly higher percentage of hypertension and IBD plus dysmetabolic criteria. Also, higher values of alanine aminotransferase and triglycerides and lower levels of high-density lipoproteins are reported in these patients. Conclusions: We suggest performing liver US screening in subjects affected by IBD to detect NAFLD earlier. Also, patients with NAFLD present several metabolic comorbidities that would fall within the new definition of metabolic-associated fatty liver disease. Finally, we encourage larger longitudinal studies, including healthy controls, to provide further confirmation of our preliminary data.

Keywords: Crohn’s disease; hepatic ultrasound; liver steatosis; metabolism; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Ludovico Abenavoli is the Guest editor of the Special Issue “Editorial Board Members’ Collection Series: Gastrointestinal and Hepatic Diseases”.

Figures

Figure 1
Figure 1
Workflow of study design. Patients were enrolled in the study and divided into different groups.
Figure 2
Figure 2
(A) US prevalence of NAFLD in IBD patients; (B) US prevalence of NAFLD in patients with CD; (C) US prevalence of NAFLD in patients with UC.

Similar articles

Cited by

References

    1. Spagnuolo R., Larussa T., Iannelli C., Cosco C., Nisticò E., Manduci E., Bruno A., Boccuto L., Abenavoli L., Luzza F., et al. COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey. Medicina. 2020;56:407. doi: 10.3390/medicina56080407. - DOI - PMC - PubMed
    1. Malik T.F., Aurelio D.M. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2023. Extraintestinal Manifestations of Inflammatory Bowel Disease. - PubMed
    1. Marotto D., Atzeni F., Ardizzone S., Monteleone G., Giorgi V., Sarzi-Puttini P. Extra-intestinal manifestations of inflammatory bowel diseases. Pharmacol. Res. 2020;161:105206. doi: 10.1016/j.phrs.2020.105206. - DOI - PubMed
    1. Martínez-Domínguez S.J., García-Mateo S., Laredo V., Gargallo-Puyuelo C.J., Gallego Llera B., López de la Cruz J., Gomollón F. Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Progression to Hepatocellular Carcinoma in Patients with Inflammatory Bowel Disease: A Systematic Review. Cancers. 2023;15:3367. doi: 10.3390/cancers15133367. - DOI - PMC - PubMed
    1. Abenavoli L., Giubilei L., Procopio A.C., Spagnuolo R., Luzza F., Boccuto L., Scarpellini E. Gut Microbiota in Non-Alcoholic Fatty Liver Disease Patients with Inflammatory Bowel Diseases: A Complex Interplay. Nutrients. 2022;14:5323. doi: 10.3390/nu14245323. - DOI - PMC - PubMed

Publication types

MeSH terms